Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure

The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts. Histone deacetylase (HDAC) inhibitors hold great promise for the pharmaceutical therapy of several malignant diseases.